There's an excellent opportunity for Canada to capitalize on its existing bone marrow transplantation centres. This is what we've done with the extension of our point-of-care manufacturing network, to roll out the manufacturing of expensive therapies, like CAR T cell, across the country. We're able to significantly lower the cost of this product, while at the same time capitalizing on existing infrastructure—
On December 5th, 2022. See this statement in context.